How high can biontech (bntx) stock go after FDA approval?
Mar 30, 2022 · BioNTech's stock was trading at $32.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BNTX shares have increased by 350.9% and is now trading at $145.07. View which stocks have been most impacted by COVID-19.
What is biontech's price expectations for the next year?
14 rows · BioNTech SE - ADR quote is equal to 175.200 USD at 2022-04-14. Based on our forecasts, a long-term ...
Is biontech efficiently growing its dividend?
BioNTech SE Sponsored ADR (BNTX) Stock Moves -1.87%: What You Should Know Apr. 22, 2022 at 5:50 p.m. ET on Zacks.com If You Invested $1,000 In BioNTech Stock At Its Pandemic Low, Here's How Much ...
Is biontech se - ADR (bntx) a good investment?
The current BioNTech SE [ BNTX] share price is $145.07. The Score for BNTX is 6, which is 88% below its historic median score of 50, and infers higher risk than normal. BNTX is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.
Is BioNTech a buy right now?
13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 8 hold r...
How has BioNTech's stock price been impacted by COVID-19 (Coronavirus)?
BioNTech's stock was trading at $32.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organi...
Are investors shorting BioNTech?
BioNTech saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 2,660,000 shares, an inc...
When is BioNTech's next earnings date?
BioNTech is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022. View our earnings forecast for BioNTech .
How can I listen to BioNTech's earnings call?
BioNTech will be holding an earnings conference call on Wednesday, March 30th at 8:00 AM Eastern. Interested parties can register for or listen to...
How were BioNTech's earnings last quarter?
BioNTech SE (NASDAQ:BNTX) posted its quarterly earnings results on Monday, November, 8th. The company reported $12.35 earnings per share (EPS) for...
What price target have analysts set for BNTX?
13 Wall Street analysts have issued 1 year price objectives for BioNTech's shares. Their forecasts range from $146.00 to $400.00. On average, they...
Who are BioNTech's key executives?
BioNTech's management team includes the following people: Prof. Ugur Sahin M.D. , Co-Founder, CEO & Member of Management Board (Age 55, Pay $716...
What is Ugur Sahin's approval rating as BioNTech's CEO?
10 employees have rated BioNTech CEO Ugur Sahin on Glassdoor.com . Ugur Sahin has an approval rating of 89% among BioNTech's employees.
BioNTech SE Stock Forecast
BioNTech SE Stock Price History
Is BioNTech SE Stock Undervalued?#N#The current BioNTech SE [ BNTX] share price is $328.35. The Score for BNTX is 72, which is 44% above its historic median score of 50, and infers lower risk than normal.
Stock Predictions
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and BNTX is experiencing buying pressure, which is a positive indicator for future bullish movement.
Vaccine catalysts to support bullish BioNTech stock forecast
Is BioNTech SE stock public?#N#Yes, BioNTech SE is a publicly traded company.
BioNTech beyond COVID-19: treatment for malaria
Factors that would favorably impact the BioNTech stock price analysis include the potential approval of the vaccine for children under the age of 12. Pfizer board member Dr. Scott Gottlieb said there is no available data as to how many children are infected by the COVID-19 virus, rather we only know how many are diagnosed.
BioNTech stock forecast and analyst sentiment
At some point, the COVID-19 pandemic will ease to the point where it becomes endemic (a disease that no longer poses the same level of risk). While that’s unlikely to happen in 2021, it could serve as a negative price driver for BioNTech stock.
FAQ
A total of 11 analysts are covering BioNTech stock, according to data from MarketBeat. At the time of writing (17 August 2021), five analysts share a buy rating, five recommend holding and one considers the stock a sell.
What is the BNT122?
Shares of BioNTech are up over the past year – and more than 2,000% higher than 2019’s IPO price. The company’s mRNA technology has proven to combat COVID-19, and could be used to treat other serious health issues.
How many Pfizer shots will be donated in 2022?
BioNTech has one drug in the phase 2 stage - BNT122 that is targeted at treating metastatic melanoma. The company’s other drugs are in the pre-clinical or phase 1 stage.
How much will Moderna make in 2021?
Earlier this week the U.S. said that it would donate 500 million doses of the Pfizer-BioNTech shot to low- and middle-income countries through the first half of 2022.
Is Pfizer in Israel?
The consensus estimates BioNTech’s 2021 Revenue at about $7 billion, while Moderna’s Revenue is estimated to come in at $8.5 billion.
BioNTech and Pfizer lined up a new manufacturing partner for their COVID-19 vaccine
Firstly, Israel has reported a drop in the efficacy of the Pfizer-Bio NTech Covid-19 vaccine in protecting against infections and symptomatic illness as the highly contagious Delta variant of the novel Coronavirus spreads in the country. However, the shot is still highly effective against protecting against severe illness and hospitalization.
Key Points
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
What happened
BioNTech and Pfizer announced a letter of intent with South African drugmaker Biovac to produce COVID-19 vaccines for distribution to African Union member countries.
So what
Shares of BioNTech ( NASDAQ:BNTX) were jumping 5.9% higher as of 2:50 p.m. EDT on Wednesday.
Now what
Biovac is expected to produce more than 100 million doses annually after it reaches full operational capacity. All of these doses will be distributed to the 55 countries in the African Union. The South African company was a natural choice as a partner to make the Pfizer-BioNTech COVID-19 vaccine.
What the FDA approval means for BioNTech
It's going to take a while before Biovac is in full swing with making COVID-19 vaccines. Pfizer and BioNTech hope to incorporate the South African company's Cape Town facility into their vaccine supply chain by year-end. Biovac's production of the COVID-19 vaccine will begin in 2022.
BNTX stock forecast
The FDA has given full approval to the COVID-19 jab from Pfizer-BioNTech. The move is positive for BNTX stock. First, it would help address the vaccine hesitancy for some people who are worried about the safety of the vaccines. While it can take years for a vaccine approval, the process was fast-tracked for COVID-19 vaccines.
How high can BNTX stock go?
According to data from CNN Business, BNTX has a median target price of $398.64 which is a premium of only about 5 percent over the current prices. Analysts don’t seem too bullish on the stock and eight of the 12 analysts rate it as a hold or some equivalent. Two analysts each rate it as a buy and a sell.
Where is Biontech located?
The street high target price for BNTX stock is $450, which is almost a 19 percent premium over the current prices. More analysts could raise the target price for BNTX after the FDA approval.
What is the difference between Biontech and Moderna?
How much will Moderna make in 2021?
BioNTech’s research pipeline is largely focused on cancer drugs (around 21 of its 27 candidates), while Moderna’s is more diverse , focusing on infectious diseases, vaccines, rare diseases, and cancer. The most advanced candidates for Moderna include an experimental vaccine for cytomegalovirus that is expected to begin phase 3 trials in 2021 and a personalized cancer vaccine mRNA-4157, to be given in combination with Merck’s MRK -0.2% Keytruda, which is currently in phase 2 of the clinical timeline. [1] BioNTech has one drug in the phase 2 stage - BNT122 that is targeted at treating metastatic melanoma. The company’s other drugs are in the pre-clinical or phase 1 stage. [2]
What is the BNT122?
The consensus estimates BioNTech’s 2021 Revenue at about $7 billion, while Moderna’s Revenue is estimated to come in at $8.5 billion.
What is mRNA technology?
BioNTech has one drug in the phase 2 stage - BNT122 that is targeted at treating metastatic melanoma. The company’s other drugs are in the pre-clinical or phase 1 stage.
